Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
13
×
life sciences
national blog main
raleigh-durham blog main
13
×
boston blog main
indiana blog main
indiana top stories
raleigh-durham top stories
san francisco blog main
san francisco top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
national
eli lilly
cancer
amgen
deals
drugs
food and drug administration
regeneron pharmaceuticals
startups
teva pharmaceutical
cancer immunotherapy
investing
What
drug
13
×
fda
approval
new
roundup
won
approved
bio
cancer
drugs
migraine
prices
therapy
annual
attention
biotech
class
companies
decades
developed
disease
friday
long
medicine
meeting
news
oks
oral
patients
potential
second
therapeutics
time
trump
acute
addresses
administration
afternoon
agency
ahead
Language
unset
Current search:
fda
×
drug
×
" raleigh-durham blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed